Stockscreener 앱 받기
1.54
3.75%
-0.06
시간 외 거래:
1.54
전일 마감가:
$1.60
열려 있는:
$1.6
하루 거래량:
7.65M
Relative Volume:
0.76
시가총액:
$421.75M
수익:
$188.87M
순이익/손실:
$-400.38M
주가수익비율:
-1.0267
EPS:
-1.5
순현금흐름:
$-260.90M
1주 성능:
-8.88%
1개월 성능:
-15.85%
6개월 성능:
-25.24%
1년 성능:
-76.34%
1일 변동 폭
$1.52
$1.65
1주일 범위
$1.52
$1.69
52주 변동 폭
$1.16
$7.005
퍼시픽 바이오 사이언스 Stock (PACB) Company Profile
명칭
Pacific Biosciences Of California Inc
전화
650-521-8000
주소
1305 O'BRIEN DRIVE, MENLO PARK, CA
PACB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.54 | 421.75M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
127.93 | 221.89B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
102.36 | 150.86B | 15.91B | 1.79B | 1.89B | 1.21 |
|
SYK
Stryker Corp
|
391.29 | 149.17B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
90.82 | 116.46B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
72.45 | 42.73B | 6.60B | 4.16B | 490.10M | 6.93 |
퍼시픽 바이오 사이언스 Stock (PACB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-04-22 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-04-18 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-12-14 | 개시 | Guggenheim | Neutral |
| 2023-12-14 | 개시 | Stephens | Overweight |
| 2023-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2023-11-17 | 업그레이드 | UBS | Neutral → Buy |
| 2023-10-31 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | 개시 | Bernstein | Outperform |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-06-30 | 개시 | Goldman | Buy |
| 2023-05-10 | 개시 | Barclays | Equal Weight |
| 2023-03-31 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | 개시 | UBS | Neutral |
| 2023-01-20 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-01-21 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-01-06 | 재개 | Piper Sandler | Neutral |
| 2021-10-15 | 재개 | Cowen | Market Perform |
| 2021-09-27 | 개시 | Canaccord Genuity | Buy |
| 2021-02-11 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-06-02 | 재개 | Cantor Fitzgerald | Overweight |
| 2020-03-09 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-10-15 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | 개시 | Cowen | Outperform |
| 2017-11-03 | 다운그레이드 | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | 다운그레이드 | CL King | Buy → Neutral |
| 2016-11-03 | 재확인 | Cantor Fitzgerald | Buy |
| 2016-06-27 | 개시 | CL King | Buy |
| 2016-04-15 | 개시 | First Analysis Sec | Overweight |
| 2016-02-04 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | 재확인 | Cantor Fitzgerald | Buy |
| 2015-10-23 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | 개시 | Cantor Fitzgerald | Buy |
| 2015-02-04 | 재확인 | Maxim Group | Buy |
| 2013-09-26 | 재확인 | Maxim Group | Buy |
| 2013-01-14 | 재확인 | Maxim Group | Buy |
모두보기
퍼시픽 바이오 사이언스 주식(PACB)의 최신 뉴스
Pacific Biosciences of California (NASDAQ:PACB) investors are sitting on a loss of 86% if they invested three years ago - Yahoo Finance
PacBio to Report Fourth Quarter 2024 Financial Results on February 13, 2025 - GlobeNewswire
Genomics Market to Grow by USD 5.21 Billion (2024-2028), Boosted by Rising Investments in R&D, with AI Impacting Market TrendsTechnavio - The Malaysian Reserve
Genomics Market to Grow by USD 5.21 Billion (2024-2028), Boosted by Rising Investments in R&D, with AI Driving Market TransformationTechnavio - The Malaysian Reserve
Menlo Park-based biotech company welcomes Florida exec to board - The Business Journals
Life sciences stocks fall on NIH funding concerns - MSN
Pacific Biosciences of California Appoints NeoGenomics CEO to Board of Directors -January 30, 2025 at 10:30 am EST - Marketscreener.com
Strategic Power Move: NeoGenomics CEO Joins PacBio Board to Accelerate Clinical Market Push - StockTitan
PACB (Pacific Biosciences of California) 5-Year Dividend Gr - GuruFocus.com
Pacific Biosciences of California (PACB) Stock Moves -1.18%: What You Should Know - MSN
Revolutionary DNA Tech Cracks Medical Mystery That Stumped Traditional Testing - StockTitan
Here's Why You Should Retain PacBio Stock in Your Portfolio for Now - MSN
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives $2.95 Consensus Price Target from Analysts - Defense World
Assenagon Asset Management S.A. Has $390,000 Stock Position in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - Defense World
JPMorgan Chase & Co. Purchases 45,957 Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB) - Defense World
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now - MSN
The Goldman Sachs Group Issues Pessimistic Forecast for Pacific Biosciences of California (NASDAQ:PACB) Stock Price - Defense World
The Goldman Sachs Group Lowers Pacific Biosciences of California (NASDAQ:PACB) Price Target to $1.75 - MarketBeat
What Analysts Are Saying About Pacific Biosciences Stock - Benzinga
PacBio Expands HiFi Sequencing Network: GIFS Becomes First Canadian Certified Provider - StockTitan
Analysts Set Pacific Biosciences of California, Inc. (NASDAQ:PACB) PT at $2.95 - MarketBeat
Brokers Issue Forecasts for PACB FY2025 Earnings - MarketBeat
Cantor Fitzgerald Comments on PACB FY2025 Earnings - Defense World
PACB Stock Falls on Preliminary Q4 Sales Miss, 7 Vega Systems Shipped - MSN
Pacific Biosciences of California (NASDAQ:PACB) Trading 8.5% HigherShould You Buy? - MarketBeat
Cantor Fitzgerald Weighs in on PACB FY2025 Earnings - MarketBeat
PACB Stock Rises After the Shipment of Vega Systems to Berry Genomics - MSN
RNA Transcriptome Profiling Tests Market Expands at 14.5% CAGR, Surpassing US$ 37 Billion by 2034 | Fact.MR Report - GlobeNewswire Inc.
Chromosome-level genome assembly of the pine wood nematode carrier Arhopalus unicolor - Nature.com
PacBio announces preliminary Q4 revenue of $39.2M - MSN
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap DownShould You Sell? - MarketBeat
PacBio Stock May Gain Following the Collaborated Launch of GutID - MSN
PACB Stock Declines Despite Promising HiFi Sequencing Findings - Yahoo Finance
Don't Ignore The Insider Selling In Pacific Biosciences of California - Simply Wall St
Selling Pacific Biosciences of California Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders - Simply Wall St
Barclays PLC Has $1.01 Million Position in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - Defense World
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Shares Bought by Barclays PLC - MarketBeat
PacBio reports drop in annual revenue, launches new products By Investing.com - Investing.com Canada
PacBio reports drop in annual revenue, launches new products - Investing.com India
PacBio's HiFi Sequencing Achieves 93% Success Rate in Breakthrough Rare Disease Study - StockTitan
PacBio Announces Preliminary Fourth Quarter and Full Year Revenue - Quantisnow
Pacific Biosciences COO Mark Van Oene sells shares for $69,979 - Investing.com India
Whole genome sequencing, assembly and annotation of the Southern Ground Hornbill – Bucorvus leadbeateri - Nature.com
Pacific Biosciences of California (NASDAQ:PACB) Stock Rating Upgraded by StockNews.com - Defense World
Pacific Biosciences COO Mark Van Oene sells shares for $69,979 By Investing.com - Investing.com Canada
퍼시픽 바이오 사이언스 (PACB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.47%
자본화:
|
볼륨(24시간):